NMR with Combined Antiangiogenic and Radiation Therapies - Breast Cancer
Abstract
The goal of the studies is to determine optimal strategies for combining radiation and drug therapies that destroy tumor vasculature using murine tumors and to elucidate microenvironmental (blood flow, oxygen, etc.) changes in the tumor to guide the planning of combined treatment. The specific aims are: Aim 1: To measure the response of murine tumors to combined radiation and drug therapies that target tumor vasculature under variations of order and timing of the two modalities. Aim 2: To measure microenvironmental changes such as blood flow and tumor oxygen following the combined therapies. The results to date have resulted in one published paper, two papers in preparation and three scientific presentations. The significant events to date include: (1) Blood flow changes are predictive of tumor response following drug therapy that is designed to target tumor vasculature. (2) Radiation therapy sensitizes drug therapy with respect to tumor response in either a single dose regimen or a fractionated schema. (3) Timing of radiation and drug therapy is critical to the magnitude of tumor response. If radiation follows drug administration, the effect of the therapies on tumor response is additive. If radiation proceeds drug delivery by 1 hour, the effect of the therapies on tumor response is more than additive. (4) The magnitude of blood flow decrease 60 hours following the combined treatment of radiation and drug is consistent with and predicts increased tumor response.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2001
- Accession Number
- ADA394673
Entities
People
- Stephen L. Brown
Organizations
- Henry Ford Health